Drugs / Ammoxetine hydrochloride enteric-coated tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05018013 | Aug 2021 → Aug 2022 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF AMMOXETINE HYDROCHLORIDE ENTERIC-COATED TABLETS (HA1406) FOR THE TREATMENT OF PATIENTS WITH DEPRESSION MET THE PRIMARY ENDPOINT irasia.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ammoxetine hydrochloride enteric-coated tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05018013 ↗ |